ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Biophytis

Biophytis (ALBPS)

0.343
0.016
( 4.89% )
Updated: 08:05:00

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.343
Bid
0.3223
Ask
0.345
Volume
24,350
0.3221 Day's Range 0.345
0.0021 52 Week Range 1.40
Market Cap
Previous Close
0.327
Open
0.327
Last Trade
1
@
0.343
Last Trade Time
07:53:10
Financial Volume
-
VWAP
-
Average Volume (3m)
38,867
Shares Outstanding
295,702,507
Dividend Yield
-
PE Ratio
-5.90
Earnings Per Share (EPS)
-0.06
Revenue
-
Net Profit
-17.03M

About Biophytis

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Paris, Paris, Fra
Founded
-
Biophytis is listed in the Biological Pds,ex Diagnstics sector of the Euronext with ticker ALBPS. The last closing price for Biophytis was 0.33 €. Over the last year, Biophytis shares have traded in a share price range of 0.0021 € to 1.40 €.

Biophytis currently has 295,702,507 shares outstanding. The market capitalization of Biophytis is 96.69 € million. Biophytis has a price to earnings ratio (PE ratio) of -5.90.

ALBPS Latest News

ADRs Close Lower; Fanhua Slips 16%

This article was automatically generated by MarketWatch using technology from Automated Insights. International stocks trading in New York closed lower Friday, as the S&P/BNY Mellon index of...

Biophytis Shares Drop 11% After Request for Meeting With FDA on Covid-19 Treatment

By Chris Wack Biophytis shares fell 11% to $2.40 after the company said it has filed for a pre-submission meeting request with the Food and Drug Administration to discuss filing for emergency use...

Biophytis to Restate Previously Issued Financial Statements

PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company...

Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patien...

PARIS and CAMBRIDGE, Mass., July 02, 2020 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specialized in the development of drug...

Biophytis Announces Results of 2019 Annual General Meeting of Shareholders

All resolutions within the competence of the Ordinary General Meeting adoptedSecond notice to reconvene the Extraordinary General Meeting to be held in the coming weeks PARIS and CAMBRIDGE...

Biophytis Enters into a Collaboration with the French Muscular Dystrophy Association (AFM-Telethon)

Provides funding for additional preclinical experiments and for the MYODA preparations for the clinical study in Duchenne muscular dystrophy (DMD) PARIS and CAMBRIDGE, Mass., June 13, 2019...

Biophytis Expands Daniel Schneiderman’s Role to Group Chief Financial Officer

PARIS and CAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics for...

Biophytis Announces Publication of its 2018 Annual Report

Files 2018 Annual Report with the AMFProvides first quarter 2019 financial statementsEnters into intellectual property agreement with Stanislas Veillet PARIS and CAMBRIDGE, Mass., May 22, 2019...

Biophytis Files Registration Statement for Proposed Initial Public Offering in the United States

PARIS and CAMBRIDGE, Mass., May 22, 2019 (GLOBE NEWSWIRE) -- Biophytis (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics for...

Biophytis Reports Annual 2018 Financial Results and Provides Operational Update

Clinical execution and advancement of our SARA program, including initiation of the SARA-INT Phase 2b clinical trial for sarcopeniaLaunch of our MYODA program for Duchenne muscular dystrophy...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.02287.120549656460.32020.350.3202269710.33161554DE
40.047816.19241192410.29520.350.293233780.3147836DE
12-0.05-12.72264631040.3930.42990.28388670.32216107DE
26-0.357-510.70.840.28485250.48378171DE
520.3375616.666666670.0061.40.002165891750.00598414DE
156-0.122-26.23655913980.4651.40.002154665030.02944993DE
2600.13564.90384615380.2082.730.002147288210.27487804DE

ALBPS - Frequently Asked Questions (FAQ)

What is the current Biophytis share price?
The current share price of Biophytis is 0.343 €
How many Biophytis shares are in issue?
Biophytis has 295,702,507 shares in issue
What is the market cap of Biophytis?
The market capitalisation of Biophytis is EUR 96.69M
What is the 1 year trading range for Biophytis share price?
Biophytis has traded in the range of 0.0021 € to 1.40 € during the past year
What is the PE ratio of Biophytis?
The price to earnings ratio of Biophytis is -5.9
What is the reporting currency for Biophytis?
Biophytis reports financial results in EUR
What is the latest annual profit for Biophytis?
The latest annual profit of Biophytis is EUR -17.03M
What is the registered address of Biophytis?
The registered address for Biophytis is 14 AVENUE DE L’OPERA, PARIS, PARIS, 75001
What is the Biophytis website address?
The website address for Biophytis is www.biophytis.com
Which industry sector does Biophytis operate in?
Biophytis operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
EIFDSTour Eiffel DS
0.0432 €
(800.00%)
89.74k
SEQUASequana medical NV
2.76 €
(33.33%)
1.64M
ALEUPEuroplasma
0.0484 €
(28.38%)
6.54M
ALPAUPaulic Meunerie SA
1.43 €
(16.26%)
17.14k
GNROGeNeuro SA
0.081 €
(15.38%)
330.33k
MLSMLSmalto
0.0125 €
(-32.43%)
50
ALVIAVialife Sa
13.30 €
(-27.72%)
7
MLMADMade
9.25 €
(-15.91%)
255
ALALOAcheterLouerFR
0.23 €
(-14.81%)
3.92k
ALLPLLepermislibre SA
0.397 €
(-11.78%)
3.01k
ATOAtos SE
0.0023 €
(-4.17%)
396.59M
BCPBanco Comercial Portugues SA
0.451 €
(0.16%)
17.85M
LATLatecoere
0.0094 €
(3.30%)
9.13M
ALVERVergnet
0.0021 €
(-4.55%)
8.37M
ALEUPEuroplasma
0.0484 €
(28.38%)
6.54M

Discussion

View Full Feed
GoonOfWallSt GoonOfWallSt 55 seconds ago
So this pile of garbage scam went through 10 million to 1 reverse splits combined just a little over a year ago and then AS was raised to 1+ trln shares and then it was diluted by scamceo into oblivion and then it was downgraded to expert markets…. And yet there are still some brain dead dilutional
RNVA
BlazingStocks BlazingStocks 58 seconds ago
$FAVO News December 12, 2024

FAVO Capital, Inc Closes $2 Million Bridge Raise Led by D. Boral Capital
https://finance.yahoo.com/news/favo-capital-inc-closes-2-133000547.html
FAVO
north40000 north40000 2 minutes ago
Arrived this past weekend on-line, I think, with "artisan"  style="font-size: 1em"voting deadline of 1/30/2025(?). The entire process is virtual to begin with, like others we received.
style="font-size: 1em"Paper process makes it easier to keep track. I hope more institutions line up
CDMO
m0n m0n 2 minutes ago
That's because you can't provide it LoL

LoL

LoL

LoL

F'ing Hilarious 

No One is Fooled 
IFUS
chemist72 chemist72 2 minutes ago
Here's somebody who got it right in 2019:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148895378
MVNT
findit findit 2 minutes ago
CBDW Biotech - 1606 Corporation (CBDW) Announces Adnexus Biotechnologies Inc. Groundbreaking AI Technology https://cbdw.ai/1606-corporation-cbdw-announces-adnexus-biotechnologies-inc-groundbreaking-ai-technology/
@CBDWInc #AI #Chatbots
CBDW
RobotDroid RobotDroid 2 minutes ago
I would love to see and be part of a plethora of lawsuits.
NWBO
 just Scottie just Scottie 2 minutes ago
Chad Chad he’s our man, if he can’t do it nobody can!
SFLM
tw0122 tw0122 3 minutes ago
Could be your Christmas today lol 3.30 + 14%
PIK
m0n m0n 3 minutes ago
Usually when claims of  false acqusations are made you post what they are LoL.

No One is Fooled by the the over Educated Stooge. 

P.S.
Where's PEACH?? All that pumping prior to the knife dropping to .025x must have made him disappear LoL


IFUS
wags23 wags23 3 minutes ago
Why didn't they have her refused? Seems obvious conflict
ENTA
Golden Cross Golden Cross 4 minutes ago
TikTok US ban starts 1-19, 2025. Federal court just upheld the law. Huge influx of new users expected for Triller.
ILLR
RobotDroid RobotDroid 4 minutes ago
100% fiction paid pumper.
NWBO
tw0122 tw0122 4 minutes ago
.40 + 58% look for NEUP open
BNOX
splintered sunlight splintered sunlight 4 minutes ago
Go get em chereb!!!!!!!!!!!!!!!!!!!!!!!

They were adding at much higher prices as well.

Oh, unless you are a Master of the Universe.
RDGL
Dallas-Cowboys Dallas-Cowboys 4 minutes ago
According to that article you are right it is going to take several months even with the new administration for the DOE to change course. Mid-year for permits hopefully Delfin charges ahead for more contracts and FID while waiting 
TGLO
quester614 quester614 4 minutes ago
I wonder what happened that caused the drastic change in Number of Beneficial Shareholders of at least 100 shares3???? Was this just a typo or an excuse to update on 11/20/24 after the 10-Q was released???????
BTW Latest shown
Transfer Agent
ClearTrust, LLC
Shareholders
XERI
tw0122 tw0122 5 minutes ago
BNOX NEUP .. style="caret-color: rgb(0, 0, 0); color: rgba(0, 0, 0, 1); font-family: -apple-system; font-size: 15px" BURLINGTON, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“
BNOX
valleybenedetto valleybenedetto 6 minutes ago
A bit of chatter on X but nothing big..still under the radar. For now. 
MRES
Golden Cross Golden Cross 6 minutes ago
$ILLR Many Reasons To Like Triller Now...

~ Launch of Triller 5.0 App.
~ Multiple Revenue Streams.
~ New CEO of Triller App is former TikTok executive Sean Kim.
~ TikTok US ban starts 1-19, 2025. Federal court just upheld the law. Huge influx of new users expec
ILLR
Golden Cross Golden Cross 7 minutes ago
$ILLR Many Reasons To Like Triller Now...

~ Launch of Triller 5.0 App.
~ Multiple Revenue Streams.
~ New CEO of Triller App is former TikTok executive Sean Kim.
~ TikTok US ban starts 1-19, 2025. Federal court just upheld the law. Huge influx of new users expec
ILLR
Smartypants2 Smartypants2 7 minutes ago
The SEC has already wiped out the debts owed to toxic lenders in similar cases.
XERI
floblu14 floblu14 7 minutes ago
FWIW - Conflict of interest might favor ENTA's appeal - one hand feeds the other B.S.

Denise Casper, the Judge in ENTA's infringement suit is married to Marc N. Casper who currently serves as president and chief executive officer of Thermo Fisher Scientific.

Thermo Fish
ENTA

Your Recent History

Delayed Upgrade Clock